DE69739169D1 - Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen - Google Patents

Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen

Info

Publication number
DE69739169D1
DE69739169D1 DE69739169T DE69739169T DE69739169D1 DE 69739169 D1 DE69739169 D1 DE 69739169D1 DE 69739169 T DE69739169 T DE 69739169T DE 69739169 T DE69739169 T DE 69739169T DE 69739169 D1 DE69739169 D1 DE 69739169D1
Authority
DE
Germany
Prior art keywords
gel
delayed release
protein substances
percent
responsible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739169T
Other languages
English (en)
Inventor
Lewis P Stratton
John F Carpenter
Mark C Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Application granted granted Critical
Publication of DE69739169D1 publication Critical patent/DE69739169D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/443Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4826Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
DE69739169T 1996-07-12 1997-07-11 Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen Expired - Lifetime DE69739169D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/679,199 US5861174A (en) 1996-07-12 1996-07-12 Temperature sensitive gel for sustained delivery of protein drugs
PCT/US1997/013479 WO1998002142A1 (en) 1996-07-12 1997-07-11 Temperature sensitive gel for sustained delivery of protein drugs

Publications (1)

Publication Number Publication Date
DE69739169D1 true DE69739169D1 (de) 2009-01-29

Family

ID=24725962

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739169T Expired - Lifetime DE69739169D1 (de) 1996-07-12 1997-07-11 Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen

Country Status (13)

Country Link
US (2) US5861174A (de)
EP (1) EP0910342B1 (de)
JP (1) JP2000514811A (de)
KR (1) KR20000023751A (de)
CN (1) CN1230108A (de)
AT (1) ATE417601T1 (de)
AU (1) AU3822497A (de)
BR (1) BR9712969A (de)
CA (1) CA2260967A1 (de)
DE (1) DE69739169D1 (de)
ES (1) ES2318860T3 (de)
IL (1) IL127976A0 (de)
WO (1) WO1998002142A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0955063A1 (de) * 1998-04-01 1999-11-10 Basf Aktiengesellschaft Verwendung von wässrigen Zusammensetzungen in subkutanen oder intramuskulär zu verabreichenden Arzneimittel
MXPA00010110A (es) * 1998-04-17 2002-08-06 Angiogenix Inc Factores angiogenicos terapeuticos y metodos para su uso.
DE60031114T2 (de) 1999-06-11 2007-05-03 Cytyc Corp., Marlborough Flüssige gelformulierung zum detektieren von milchkanälen in der brust vor einer chirurgischen ablation des brustgewebes
WO2001010482A1 (en) * 1999-08-05 2001-02-15 Biocardia, Inc. A system and method for delivering thermally sensitive and reverse-thermal gelation matrials
US7767197B2 (en) 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
AU2001273041A1 (en) * 2000-06-26 2002-01-08 Board Of Regents Of The University Of Nebraska Methods for use of delivery composition for expanding, activating, committing ormobilizing one or more pluripotent, self-renewing and committed stem cells
ATE316786T1 (de) * 2000-11-22 2006-02-15 Rxkinetix Inc Behandlung von mukositis
US6565530B2 (en) 2001-02-28 2003-05-20 Scimed Life Systems, Inc. Immobilizing objects in the body
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
BR0210628A (pt) * 2001-06-29 2004-08-10 Becton Dickinson Co Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
AU2002335815A1 (en) * 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
ATE319760T1 (de) * 2001-12-21 2006-03-15 Isotis Orthobiologics Inc Zusammensetzungen enthaltend endgruppen-verkappte polyalkylenglykole
US7205337B2 (en) * 2001-12-21 2007-04-17 Isotis Orthobiologics, Inc. End-capped polymers and compositions containing such compounds
ATE391742T1 (de) * 2002-02-15 2008-04-15 Nektar Therapeutics Al Corp Hydrolytisch abbaubare polyalkylenoxid-polymere
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
DE10326152A1 (de) * 2003-06-06 2005-01-05 Aventis Pharma Deutschland Gmbh Verfahren und Vorrichtung zur quantitativen Analyse von Lösungen und Dispersionen mittels Nahinfrarot-Spektroskopie
US20050118261A1 (en) * 2003-06-12 2005-06-02 Oien Hal J. Compositions and methods of administering doxepin to mucosal tissue
AU2004315509A1 (en) * 2003-12-05 2005-08-18 Becton, Dickinson And Company Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
CA2635603C (en) * 2005-11-30 2016-01-19 Endo Pharmaceuticals Inc. Treatment of xerostomia
US20070191816A1 (en) * 2006-02-13 2007-08-16 Boston Scientific Scimed, Inc. Radio frequency induced drug elution
AU2007224940B2 (en) * 2006-03-10 2013-08-29 Pivot Europe Pharmaceuticals Ag Method for solubilizing, dispersing, and stabilizing materials, products manufactured according to said method, and use thereof
US8608760B2 (en) * 2006-06-21 2013-12-17 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for joining non-conjoined lumens
US8197499B2 (en) * 2006-06-21 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for joining non-conjoined lumens
EP2034906A4 (de) * 2006-06-21 2010-07-28 Univ Leland Stanford Junior Zusammensetzungen und verfahren zur verbindung nicht untereinander verbundener lumen
EP2124556B1 (de) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US8043604B2 (en) * 2007-04-27 2011-10-25 Pluromed, Inc. Ultrasonography using time- and temperature-sensitive variable adhesion coupling gels
CN101450035B (zh) * 2007-12-07 2010-09-29 福建医科大学附属协和医院 一种用于肿瘤局部消融治疗的双重缓释生物制剂
EP2224968A2 (de) * 2007-12-20 2010-09-08 Tautona Group, L.P. Zusammensetzungen und verfahren zur verbindung nicht untereinander verbundener lumen
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2009111173A2 (en) * 2008-02-29 2009-09-11 Pluromed, Inc. Local embolization via heating of thermosensitive polymers
RU2499592C2 (ru) 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
WO2009139924A2 (en) 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8399018B2 (en) * 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
AU2009274137B2 (en) * 2008-07-21 2013-10-31 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8563037B2 (en) * 2009-02-06 2013-10-22 Tautona Group, L.P. Compositions and methods for joining non-conjoined lumens
KR20110124780A (ko) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
US10500384B2 (en) * 2010-01-08 2019-12-10 Wake Forest University Health Sciences Delivery system
US8642502B2 (en) 2010-10-11 2014-02-04 TRGel, LLC Reversible gel-forming compositions for controlled delivery of bioactive substances
AU2012225644B2 (en) 2011-03-07 2017-05-04 Wake Forest University Health Sciences Delivery system
BR112013024863A2 (pt) * 2011-03-28 2016-12-20 Yissum Res Dev Co formulação injetável de liberação sustentada
JP2016534121A (ja) 2013-08-27 2016-11-04 オトノミ—,インク. 小児の耳の病気の処置
EP3125905A4 (de) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Verfahren und zusammensetzungen für mikrobiomveränderung
KR20170021353A (ko) 2014-07-03 2017-02-27 오토노미, 인코포레이티드 시프로플록사신 조성물의 멸균
WO2016148201A1 (ja) * 2015-03-17 2016-09-22 参天製薬株式会社 ポリペプチドを含有する医薬組成物
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
EP3846830A4 (de) 2018-09-05 2022-07-06 Solarea Bio, Inc. Verfahren und zusammensetzungen zur behandlung von muskel-skelett-erkrankungen
EP3986163A2 (de) 2019-06-19 2022-04-27 Solarea Bio, Inc. Mikrobielle zusammensetzungen und verfahren zur herstellung von aufgewerteten probiotischen zusammenstellungen
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
US5328695A (en) * 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4702917A (en) * 1985-11-18 1987-10-27 Research Triangle Institute Porous bioabsorbable polyesters
US4954154A (en) * 1986-03-26 1990-09-04 The O. M. Scott & Sons Company Controlled release fertilizer gel composition and process for its production
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
DE4002736A1 (de) * 1990-01-31 1991-08-01 Hoechst Ag Biologisch abbaubare polymere, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5306501A (en) * 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
CA2044878C (en) * 1990-08-07 2000-12-26 Tacey X. Viegas Thermally reversible and irreversible gels
US5124151A (en) * 1990-08-07 1992-06-23 Mediventures Inc. Drug delivery by injection with thermo-irreversible gels
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5077033A (en) * 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5411737A (en) * 1991-10-15 1995-05-02 Merck & Co., Inc. Slow release syneresing polymeric drug delivery device
EP0551626A1 (de) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible Gel als pharmazeutische Grundmasse für eine galenische Form
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
IT1255460B (it) * 1992-07-28 1995-11-02 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
FR2694559B1 (fr) * 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
PT686045E (pt) * 1993-02-23 2001-04-30 Genentech Inc Estabilizacao por excipientes de polipeptidos tratados com solventes organicos
US5420197A (en) * 1994-01-13 1995-05-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
US5554147A (en) * 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients

Also Published As

Publication number Publication date
IL127976A0 (en) 1999-11-30
WO1998002142A1 (en) 1998-01-22
US5861174A (en) 1999-01-19
EP0910342A1 (de) 1999-04-28
ATE417601T1 (de) 2009-01-15
AU3822497A (en) 1998-02-09
EP0910342B1 (de) 2008-12-17
ES2318860T3 (es) 2009-05-01
CA2260967A1 (en) 1998-01-22
US6482435B1 (en) 2002-11-19
KR20000023751A (ko) 2000-04-25
CN1230108A (zh) 1999-09-29
BR9712969A (pt) 2002-02-05
EP0910342A4 (de) 2006-03-22
JP2000514811A (ja) 2000-11-07

Similar Documents

Publication Publication Date Title
DE69739169D1 (de) Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
DE602004024463D1 (de) RGD-angereicherte gelatineähnliche Proteine mit verstärkter Zellbindung
EP0921818A4 (de) Therapeutische und diagnostische verfahren und zusammensetzungenauf der basis von jagged/notch-proteinen und aminosäuren
ATE189475T1 (de) Wachstums-differenzierungsfaktor der tgf-b familie
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
DE69836131D1 (de) Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
RU2227743C2 (ru) Полипептидные варианты с повышенной гепаринсвязывающей способностью
WO2000002916A3 (en) PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY
DE69534165D1 (de) Adenovirus mit glutathion peroxydate gene
ATE335758T1 (de) Peptidzusammensetzung mit wachstumsfaktor- ähnlicher aktivität
DE60018564D1 (de) Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DE69014046D1 (de) Verzweigungsenzym und dessen Verwendung.
ATE205855T1 (de) Gegen bakterien, mycota und viren wirksame vertebraten proteine und dessen kosmetische zubereitungen
ES2167939T3 (es) Nuevas poliaminas, su preparacion y usos.
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
BR9812138A (pt) Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
BR9814958A (pt) Proteìna de cimento de tecido, composição farmacêutica, uso da proteìna de cimento de tecido, vacina, processos para produção de vacina, para ligação de tecido de animal e para preparação de uma protéina de cimento de tecido, molécula de ácido nucleico, vetor de expressão ou de clonagem, célula hospedeira, e, animal transgênico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition